Precigen Inc

Market Summary

USD1.18+0.01

Market Closed

0.85%

PGEN Stock Price

View Fullscreen

PGEN RSI Chart

PGEN Valuation

Market Cap

302.6M

Price/Earnings (Trailing)

-3.56

Price/Sales (Trailing)

13.69

EV/EBITDA

-3.8

Price/Free Cashflow

-4.51

PGEN Price/Sales (Trailing)

PGEN Profitability

EBT Margin

-385.21%

Return on Equity

-57.57%

Return on Assets

-44.59%

Free Cashflow Yield

-22.18%

PGEN Fundamentals

PGEN Revenue

Revenue (TTM)

22.1M

Revenue Y/Y

-39.3%

Revenue Q/Q

-4.54%

PGEN Earnings

Earnings (TTM)

-85.0M

Earnings Y/Y

-122.65%

Earnings Q/Q

2.58%

Price Action

Last 7 days

-0.8%

Last 30 days

-6.3%

Last 90 days

-27.2%

Trailing 12 Months

-25.8%

How does PGEN drawdown profile look like?

PGEN Financial Health

Current Ratio

2.83

PGEN Investor Care

Shares Dilution (1Y)

23.18%

Diluted EPS (TTM)

-0.37

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	23.2M	22.1M	0	0
2022	16.3M	15.4M	28.8M	26.9M
2021	97.9M	71.2M	51.0M	35.3M
2020	98.0M	95.6M	100.8M	103.2M
2019	134.1M	121.7M	107.5M	90.7M
2018	217.1M	208.0M	194.4M	151.2M
2017	201.2M	203.2M	200.2M	231.2M
2016	183.2M	190.8M	186.4M	190.9M
2015	97.9M	131.0M	163.2M	173.6M
2014	27.7M	32.8M	48.0M	71.9M
2013	16.1M	20.1M	23.2M	23.8M
2012	9.5M	10.9M	12.3M	13.8M
2011	0	0	0	8.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Latest Insider Trading transactions for PGEN

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 22, 2023	mitchell dean j	bought	35,250	1.41	25,000	-
Aug 25, 2023	sabzevari helen	sold	-117,763	1.53	-76,969	president and ceo
Aug 24, 2023	shah rutul r	sold	-8,836	1.64	-5,388	chief operating officer
Aug 24, 2023	lehr donald p.	sold	-17,953	1.64	-10,947	chief legal officer
Aug 24, 2023	perez jeffrey thomas	sold	-14,581	1.64	-8,891	svp, ip affairs
Aug 24, 2023	thomasian harry jr.	sold	-14,833	1.64	-9,045	chief financial officer
Aug 23, 2023	shah rutul r	acquired	-	-	15,480	chief operating officer
Aug 23, 2023	thomasian harry jr.	acquired	-	-	17,934	chief financial officer
Aug 23, 2023	sabzevari helen	acquired	-	-	141,587	president and ceo
Aug 23, 2023	lehr donald p.	acquired	-	-	21,710	chief legal officer

Which funds bought or sold PGEN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Dec 06, 2023	CITIGROUP INC	reduced	-92.69	-46,626	4,628	-%
Nov 24, 2023	DEUTSCHE BANK AG\	unchanged	-	15,457	81,292	-%
Nov 22, 2023	Graham Capital Management, L.P.	reduced	-46.21	-13,950	27,596	-%
Nov 17, 2023	JACOBS LEVY EQUITY MANAGEMENT, INC	reduced	-49.22	-581,094	976,667	0.01%
Nov 16, 2023	Creative Planning	added	0.94	64,460	326,092	-%
Nov 15, 2023	Opaleye Management Inc.	new	-	1,318,470	1,318,470	0.43%
Nov 15, 2023	Tudor Investment Corp Et Al	unchanged	-	19,295	101,479	-%
Nov 15, 2023	JANE STREET GROUP, LLC	new	-	46,816	46,816	-%
Nov 15, 2023	GSA CAPITAL PARTNERS LLP	new	-	475,000	475,000	0.04%
Nov 15, 2023	MORGAN STANLEY	added	3.41	299,464	1,380,880	-%

Latest Funds Activity

Are funds buying PGEN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PGEN

No. of Funds

Schedule 13G FIlings of Precigen Inc

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 31, 2023	kirk randal j	38.3%	96,360,443	SC 13D/A
Jan 27, 2023	ares trading s.a.	9.92%	20,647,152	SC 13G/A
Jan 24, 2022	ares trading s.a.	9.99%	20,647,152	SC 13G/A
Feb 16, 2021	miller value partners, llc	3.85%	7,134,094	SC 13G/A
Jan 08, 2021	ares trading s.a.	14.8%	27,398,519	SC 13G/A
Dec 21, 2020	kirk randal j	43.6%	81,822,163	SC 13D/A
Aug 13, 2020	kirk randal j	48.7%	8.4e+07	SC 13D/A
Feb 14, 2020	miller value partners, llc	5.17%	8,416,710	SC 13G
Feb 04, 2020	kirk randal j	48.2%	81,523,936	SC 13D/A
Jan 22, 2020	ares trading s.a.	14.9%	24,852,348	SC 13G/A

Recent SEC filings of Precigen Inc

View All Filings

Date Filed	Form Type	Document
Nov 09, 2023	8-K	Current Report
Nov 09, 2023	10-Q	Quarterly Report
Sep 25, 2023	4	Insider Trading

Peers (Alternatives to Precigen Inc)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
HILS	31.5B	-	6.13%	411799.31%	-3.7K	218.4K	-	-102.45%
MRNA	30.6B	10.7B	12.59%	-56.51%	-8.83	2.87	-53.67%	-129.46%
ALNY	21.3B	1.7B	0.38%	-28.56%	-41.84	12.38	79.37%	56.87%
BMRN	17.5B	2.3B	8.71%	-10.95%	119.09	7.58	15.05%	75.21%
INCY	12.3B	3.6B	1.18%	-34.97%	28.84	3.4	8.35%	-51.49%
MID-CAP
APLS	7.4B	272.9M	33.62%	24.68%	-12.26	27.23	141.38%	4.43%
BBIO	5.7B	-	10.65%	240.88%	-9.69	48.33	54.84%	-12.96%
ACAD	3.4B	631.9M	-9.53%	43.40%	-23.12	5.44	23.54%	31.53%
AXSM	3.3B	223.4M	14.00%	-9.85%	-16.45	14.86	-	-26.24%
ARWR	2.6B	240.7M	-11.63%	-24.14%	-12.52	10.67	-1.03%	-16.59%
SMALL-CAP
CPRX	1.5B	348.4M	12.92%	-15.71%	24.33	4.33	81.69%	-7.29%
NVAX	661.3M	1.0B	-18.09%	-67.84%	-1.2	0.63	-43.15%	58.48%
INO	100.5M	6.4M	-	-79.35%	-0.61	15.6	-44.11%	50.48%
IBIO	37.6M	-	385.71%	119.35%	-0.58	-	-	-29.23%
CRBP	23.7M	-	40.31%	4064.72%	-0.5	-	-	-13.74%

Precigen Inc News

Latest updates

Stocks Register • 09 Dec 2023 • 08:05 pm • 89 minutes ago

Analyst JP Morgan Price Target And Rating For Precigen Inc (PGEN ...

InvestorPlace • 22 Nov 2023 • 08:00 am • 17 days ago

3 Penny Stocks to Buy to Turn $1 into $100: November 2023

InvestorsObserver • 10 Nov 2023 • 08:00 am • 29 days ago

Should You Buy Precigen Inc (PGEN) Stock After it Has Fallen 14.05% in a Week?

PR Newswire • 09 Nov 2023 • 08:00 am • 30 days ago

Precigen Reports Third Quarter 2023 Financial Results and ...

Best Stocks • 09 Nov 2023 • 07:06 am • 30 days ago

Agenus Q3 Financial Results Resilience and Growth in the ...

PR Newswire • 07 Nov 2023 • 08:00 am • 32 days ago

Precigen to Participate in the Stifel 2023 Healthcare Conference

Simply Wall St • 04 Nov 2023 • 07:00 am • 35 days ago

Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?

Simply Wall St • 08 Sep 2023 • 07:00 am • 3 months ago

Institutions along with private equity firms who hold considerable shares inPrecigen, Inc. (NASDAQ:PGEN) come under pressure; lose 11% of holdings value

Yahoo Finance • 05 Sep 2023 • 07:00 am • 3 months ago

Should You Buy Precigen, Inc. (PGEN) After Golden Cross?

Seeking Alpha • 28 Aug 2023 • 07:00 am • 3 months ago

Precigen's Express Lane: Racing Towards RRP Remedies (Rating ...

Seeking Alpha • 23 Aug 2023 • 07:00 am • 3 months ago

Agenus to cut 25% staff as lead program takes priority

Simply Wall St • 17 Aug 2023 • 07:00 am • 3 months ago

Fred Hassan Bought 185% More Shares In Precigen

Penny Stocks • 17 Aug 2023 • 07:00 am • 3 months ago

10 Top Penny Stocks To Buy According To Insiders In August

PR Newswire • 14 Aug 2023 • 07:00 am • 3 months ago

Scott+Scott Attorneys at Law LLP Announce Pendency of Class ...

PR Newswire • 14 Aug 2023 • 07:00 am • 3 months ago

Levi & Korsinsky LLP notifies shareholders of BMRN, MAXR, SYF ...

Financials for Precigen Inc

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	-4.5%	1,767,000	1,851,000	1,763,000	16,722,000	2,911,000	5,513,000	3,684,000	3,333,000	3,815,000	24,511,000	19,333,000	23,583,000	30,424,000	29,838,000	17,002,000	18,299,000	32,836,000	22,585,000	33,789,000	32,448,000	45,275,000
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	71,660,000	73,395,000	82,038,000	380,002,500	98,919,000	95,010,000
S&GA Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	24,741,000	21,483,000	33,594,000	24,935,000	38,708,000	34,427,000
R&D Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	31,480,000	34,518,000	33,062,000	280,449,500	44,885,000	42,049,000
EBITDA Margin	2.1%	-2.68	-2.74	-2.25	-	-1.05	-1.09	-0.73	-1.53	-1.45	-0.72	-0.77	-1.10	-1.35	-1.12	-	-	-	-	-	-	-
Interest Expenses	-74.9%	232,000	924,000	348,000	4,619,000	33,000	3,535,000	39,000	3,538,000	39,000	3,539,000	47,000	3,543,000	44,000	3,568,000	-2,551,000	4,471,000	4,358,000	77,000	-372,000	3,999,000	142,000
Income Taxes	-18.2%	-65,000	-55,000	-90,500	-50,000	-89,000	-58,000	-164,000	-	-	4,000	-130,000	8,000	-	40,000	-451,500	-512,000	-525,000	30,000	4,110,000	-14,322,000	-1,127,000
Earnings Before Taxes	10.6%	-20,384,000	-22,789,000	-22,168,000	-7,694,000	-26,148,000	-23,956,000	-29,188,500	-26,380,000	-30,999,000	-21,896,000	-40,303,000	-27,586,000	-15,829,000	-20,806,000	-36,980,000	-49,057,000	-32,314,000	-52,913,000	-203,393,000	-73,068,000	-67,956,000
EBT Margin	2.5%	-3.30	-3.39	-2.97	-	-1.24	-1.29	-0.93	-1.77	-1.69	-0.96	-1.01	-1.28	-1.55	-1.36	-	-	-	-	-	-	-
Net Income	10.6%	-20,319,000	-22,734,000	-22,176,000	87,379,000	-17,635,000	-19,251,000	-25,034,000	-29,764,000	-20,050,000	-17,318,000	-41,661,000	-29,508,000	-43,354,000	-55,998,000	-169,215,000	-53,634,000	-38,766,000	-60,709,000	-340,465,000	-57,324,000	-65,382,000
Net Income Margin	-6.2%	1.00	1.07	1.05	-	-1.14	-1.15	-0.89	-1.57	-1.52	-1.35	-1.65	-2.96	-3.21	-3.00	-	-	-	-	-	-	-
Free Cashflow	14.4%	-15,869,000	-18,542,000	-15,449,000	-25,387,000	-8,771,000	-20,362,000	-17,362,000	-19,288,000	-8,970,000	-17,398,000	-17,938,000	-20,028,000	-15,687,000	-30,895,000	-	-	-	-	-	-	-

Balance Sheet
(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Assets	-8.1%	191	208	242	216	259	321	336	360	377	403	407	315	336	362	405	456	605	655	710	716	980
Current Assets	-12.0%	93.00	106	138	118	163	165	155	157	153	157	144	149	151	173	189	235	157	183	232	285	310
Cash Equivalents	-37.5%	10.00	17.00	10.00	5.00	9.00	50.00	41.00	43.00	42.00	37.00	28.00	52.00	28.00	47.00	38.00	68.00	45.00	59.00	107	110	90.00
Net PPE	8.2%	7.00	7.00	7.00	7.00	8.00	8.00	34.00	9.00	33.00	33.00	34.00	35.00	45.00	47.00	60.00	44.00	123	120	136	87.00	123
Goodwill	-0.2%	37.00	37.00	37.00	37.00	37.00	37.00	54.00	38.00	54.00	54.00	54.00	54.00	54.00	54.00	64.00	54.00	148	150	151	94.00	151
Liabilities	4.1%	43.00	41.00	57.00	90.00	117	266	262	253	246	243	232	247	278	312	317	384	376	376	375	337	425
Current Liabilities	6.8%	33.00	31.00	47.00	79.00	105	30.00	26.00	35.00	29.00	29.00	25.00	42.00	31.00	64.00	71.00	123	82.00	52.00	59.00	62.00	92.00
Short Term Borrowings	-	-	-	14.00	43.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Current	-	-	-	-	43.00	82.00	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	32.00	32.00	32.00	31.00	0.00	1.00	0.00	1.00
LT Debt, Non Current	-	-	-	-	-	-	199	201	180	180	177	174	172	194	191	189	186	184	212	214	211	183
Shareholder's Equity	-11.1%	148	166	184	126	143	56.00	74.00	107	131	159	175	67.00	59.00	50.00	87.00	72.00	228	279	335	379	555
Retained Earnings	-1.0%	-1,931	-1,911	-1,891	-1,868	-1,846	-1,933	-1,916	-1,915	-1,890	-1,860	-1,840	-1,823	-1,781	-1,752	-1,708	-1,652	-1,483	-1,430	-1,391	-1,330	-990
Additional Paid-In Capital	0.1%	2,083	2,080	2,078	1,998	1,996	1,994	1,992	2,023	2,020	2,017	2,014	1,887	1,839	1,802	1,797	1,752	1,745	1,737	1,733	1,722	1,552
Shares Outstanding	0.4%	256	255	255	208	208	200	200	207	199	199	193	188	166	164	160	163	154	153	153	130	129
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	22.00	16.00	16.00

Cashflow (Last 12 Months)
(In Millions)

Cashflow (Quarterly)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	-7.9%	-17,008,000	-15,768,000	-18,388,000	-15,396,000	-23,813,000	-7,053,000	-18,783,000	-14,589,000	-17,022,000	-7,776,000	-16,384,000	-16,469,000	-19,004,000	-13,805,000	-27,743,000	-32,142,000	-27,148,000	-33,403,000	-43,234,000	-37,362,000	-28,820,000
Share Based Compensation	5.3%	2,306,000	2,189,000	3,131,000	2,210,000	2,125,000	2,309,000	3,562,000	2,442,000	2,490,000	3,557,000	5,415,000	4,497,000	4,600,000	4,897,000	4,372,000	4,412,000	5,423,000	61,000	9,054,000	7,956,000	8,132,000
Cashflow From Investing	-55.2%	10,525,000	23,503,000	-50,408,000	11,421,000	181,855,000	16,573,000	16,568,000	15,929,000	22,013,000	16,620,000	-129,102,000	40,184,000	181,000	23,967,000	-36,553,000	54,509,000	13,777,000	-15,027,000	33,592,000	30,741,000	-161,034,000
Cashflow From Financing	100.0%	-	-14,585,000	44,174,000	-39,282,000	-115,734,000	-113,000	-163,000	-110,000	234,000	23,000	121,040,000	-72,000	-114,000	-1,260,000	34,151,000	1,199,000	45,000	-33,000	6,927,000	27,249,000	193,600,000

PGEN Income Statement

2023-09-30

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating Expenses
Impairment of goodwill			$ 0	$ 482
Impairment of other noncurrent assets			0	638
Other income (Expense), Net
Equity in net income (loss) of affiliates			0	861
Loss from continuing operations before income taxes	$ (19,801)	$ (7,694)	(62,974)	(57,798)
Income tax benefit	6	50	126	197
Income from discontinued operations, net of income taxes	0	95,023	0	108,094
Net (loss) income	$ (19,795)	$ 87,379	$ (62,848)	$ 50,493
Net (loss) income per share
Net loss from continuing operations per share, basic (in dollars per share)	$ (0.08)	$ (0.04)	$ (0.26)	$ (0.29)
Net loss from continuing operating per share, diluted (in dollars per share)	(0.08)	(0.04)	(0.26)	(0.29)
Net income from discontinued operations per share, diluted (in dollars per share)	0	0.48	0	0.54
Net income from discontinued operations per share, basic (in dollars per share)	0	0.48	0	0.54
Net (loss) income per share, basic (in dollars per share)	(0.08)	0.44	(0.26)	0.25
Net (loss) income per share, diluted (in dollars per share)	$ (0.08)	$ 0.44	$ (0.26)	$ 0.25
Weighted average shares outstanding, basic (in shares)	248,520,724	200,670,590	243,075,262	200,256,046
Weighted average shares outstanding, diluted (in shares)	248,520,724	200,670,590	243,075,262	200,256,046
Continuing Operations
Revenues
Total revenues	$ 1,379	$ 16,722	$ 4,997	$ 25,146
Operating Expenses
Research and development	11,583	12,622	35,620	36,377
Selling, general and administrative	9,196	10,137	30,150	36,496
Impairment of goodwill	0	0	0	482
Impairment of other noncurrent assets	0	0	0	638
Total operating expenses	22,316	24,336	70,531	79,075
Operating loss	(20,937)	(7,614)	(65,534)	(53,929)
Other income (Expense), Net
Interest expense	(1)	(2,036)	(461)	(6,137)
Interest income	856	56	2,316	131
Other income, net	281	1,038	705	1,276
Total other income (expense), net	1,136	(942)	2,560	(4,730)
Equity in net income (loss) of affiliates	0	862	0	861
Loss from continuing operations before income taxes	(19,801)	(7,694)	(62,974)	(57,798)
Income tax benefit	6	50	126	197
Loss from continuing operations	(19,795)	(7,644)	(62,848)	(57,601)
Continuing Operations \| Collaboration and licensing revenues
Revenues
Total revenues	0	14,561	0	14,561
Continuing Operations \| Product revenues
Revenues
Total revenues	82	342	730	1,455
Continuing Operations \| Service revenues
Revenues
Total revenues	1,296	1,750	4,261	8,896
Operating Expenses
Cost of products and services	1,537	1,577	4,761	5,082
Continuing Operations \| Other revenues
Revenues
Total revenues	$ 1	$ 69	$ 6	$ 234

PGEN Balance Sheet

2023-09-30

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 10,076,000	$ 4,858,000
Restricted cash	0	43,339,000
Short-term investments	63,679,000	51,092,000
Receivables
Trade, less allowance for credit losses of $184 as of both September 30, 2023 and December 31, 2022	988,000	978,000
Other	13,117,000	12,826,000
Prepaid expenses and other	5,128,000	5,066,000
Total current assets	92,988,000	118,159,000
Long-term investments	5,271,000	0
Property, plant and equipment, net	7,115,000	7,329,000
Intangible assets, net	40,426,000	44,455,000
Goodwill	36,894,000	36,923,000
Right-of-use assets	7,197,000	8,086,000
Other assets	797,000	1,025,000
Total assets	190,688,000	215,977,000
Current liabilities
Accounts payable	2,351,000	4,068,000
Accrued compensation and benefits	6,621,000	6,377,000
Other accrued liabilities	4,119,000	4,997,000
Settlement and indemnification accruals	18,075,000	18,750,000
Deferred revenue	509,000	25,000
Current portion of long-term debt	0	43,219,000
Current portion of lease liabilities	1,200,000	1,209,000
Total current liabilities	32,875,000	78,645,000
Deferred revenue, net of current portion	1,818,000	1,818,000
Lease liabilities, net of current portion	6,192,000	6,992,000
Deferred tax liabilities	2,125,000	2,263,000
Total liabilities	43,010,000	89,718,000
Commitments and contingencies (Note 14)
Shareholders' equity
Common stock, no par value, 400,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 256,398,527 shares and 208,150,021 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	0	0
Additional paid-in capital	2,082,654,000	1,998,314,000
Accumulated deficit	(1,931,415,000)	(1,868,567,000)
Accumulated other comprehensive loss	(3,561,000)	(3,488,000)
Total shareholders' equity	147,678,000	126,259,000
Total liabilities and shareholders' equity	$ 190,688,000	$ 215,977,000

About Precigen Inc

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. The company operates through two segments, Biopharmaceuticals and Exemplar. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and Lactococcus lactis, a food-grade bacterium. Additionally, it provides RheoSwitch Therapeutic System, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

CEO	Dr. Helen Sabzevari MPH, Ph.D.
WEBSITE	precigen.com
EMPLOYEES	209

Precigen Inc Frequently Asked Questions

What is the ticker symbol for Precigen Inc? What does PGEN stand for in stocks?

PGEN is the stock ticker symbol of Precigen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Precigen Inc (PGEN)?

As of Fri Dec 08 2023, market cap of Precigen Inc is 302.55 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PGEN stock?

You can check PGEN's fair value in chart. The fair value of Precigen Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Precigen Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PGEN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Precigen Inc a good stock to buy?

The fair value guage provides a quick view whether PGEN is over valued or under valued. Whether Precigen Inc is cheap or expensive depends on the assumptions which impact Precigen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PGEN.

What is Precigen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 08 2023, PGEN's PE ratio (Price to Earnings) is -3.56 and Price to Sales (PS) ratio is 13.69. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PGEN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Precigen Inc's stock?

In the past 10 years, Precigen Inc has provided -0.244 (multiply by 100 for percentage) rate of return.

Market Summary

PGEN Stock Price

PGEN RSI Chart

PGEN Valuation

PGEN Price/Sales (Trailing)

PGEN Profitability

PGEN Fundamentals

PGEN Revenue

PGEN Earnings

Price Action

How does PGEN drawdown profile look like?

PGEN Financial Health

PGEN Investor Care

Historical Charts for Stock Metrics

Latest Insider Trading transactions for PGEN

Which funds bought or sold PGEN recently?

Latest Funds Activity

Schedule 13G FIlings of Precigen Inc

Recent SEC filings of Precigen Inc

Peers (Alternatives to Precigen Inc)

Precigen Inc News

Financials for Precigen Inc

Income Statement (Last 12 Months)

Balance Sheet.css-zgnqz2{margin:0;font-family:"Roboto","Helvetica","Arial",sans-serif;font-weight:400;font-size:0.75rem;line-height:1.66;letter-spacing:0.03333em;color:#595959;}(In Millions)

Cashflow (Last 12 Months)(In Millions)

PGEN Income Statement

PGEN Balance Sheet

About Precigen Inc

Precigen Inc Frequently Asked Questions

What is the ticker symbol for Precigen Inc? What does PGEN stand for in stocks?

What is the market capital of Precigen Inc (PGEN)?

What is the fair value of PGEN stock?

Is Precigen Inc a good stock to buy?

What is Precigen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

What is 5 year return on Precigen Inc's stock?

Balance Sheet
(In Millions)

Cashflow (Last 12 Months)
(In Millions)